Replies to post #137033 on PharmaCyte Biotech Inc (PMCB)

[thenewmixer]

Still no proof of ciab works ...only FDA putting pmcb on hold...no proof of anything...none....zilch...nada!

[DragonBear]

Still no proof of scam...

From last June in reply. Where small cap refers to a biotech small caps:

Prove it's a scam....prove it's not

Since there is the dream of up listing on the NAS:

Find a small cap with an O/S exceeding 1B.

Find a small cap who has $142K in cash, or enough to last the next 2 yrs to fund CTs.

(Updated to $4.2M, which still isn't enough)

Find a small cap without a product on the market whose R&D vs insider cash compensation is 1:7.

Find a small cap who after 6-8 yrs of being listed doesn't have at least 1 drug in advanced CTs.

Find a small cap where 3 yrs after taking over, the CEO didn't realize there was such a thing as pre-clinical tests required. A CEO who 2 yrs after taking over told SHs a clinical trial would be started by EOY (2016) without ever having performed pre-clinical testing.

Add on an IND hold. With Kenny not interested in posting the FDA response for the hold in an 8K filing. If it's just some trivial non-consequential matter of a few tests needing to be performed, why not release the FDA letter? So SHs could see it was trivial. Now what harm could that cause? LOL

only FDA wanting more info...

Yes info likely not available from the Lohr studies 20 yrs ago. Buried in the FDA letter Kenny refuses to show SHs.

no proof of RS...none....zilch...nada!

"Patience"! That comes later. When Kenny has to try to issue 5B shares at a discount price of 0.0005 to the 3rd party block buyers (to pay his salary), and they still aren't interested in buying em, then he'll perform the R/S. Easier for the 3rd parties to dump less shares, at a higher post R/S price, with a profitable discount price. Then Kenny gets his salary, and the scam keeps rolling along.

[concordia]

I would say this proves its a SCAM. And this is only one example. PR from almost 5 years ago


https://pharmacyte.com/pharmacyte-biotech-schedule-2016-cancer-clinical-trial-pancreatic-cancer/



PharmaCyte Biotech on Schedule for 2016 Cancer Clinical Trial in Pancreatic Cancer

25 FEB 16

SILVER SPRING, Md., Feb. 24, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, issued a further update on its upcoming clinical trial in pancreatic cancer. In this update, PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, clarifies statements made earlier this week that reportedly confused numerous shareholders and potential investors.
“Last Monday I tried to address certain issues that shareholders and potential investors have raised repeatedly about our upcoming clinical trial and provide an update on our efforts to complete the process of preparing the Investigational New Drug application (IND) that PharmaCyte must submit to the FDA to start our clinical trial in pancreatic cancer. Given the number of telephone calls and emails the Company has received since that update was published, it has become apparent that the update caused confusion and raised issues of concern that were never intended.
“When it was stated on Monday that the expected ‘start date’ for PharmaCyte’s clinical trial in pancreatic cancer remains difficult to announce with certainty, we were not implying that we aren’t still on schedule to get into the clinic in 2016 or that we don’t have any idea when we will be in the clinic. We plan to be in the clinic well before the end of this year. It was simply a statement that intended to refrain from announcing a specific date or time period for starting the trial because much of what is left to complete is out of our control.
“PharmaCyte is involved in a well-planned, detailed and methodical process to insure that every aspect of the IND is correct before we submit the IND to the FDA. As the “Sponsor” of the IND, it is our responsibility to insure that the Chemistry, Manufacturing and Controls (CMC) section of the IND is complete and accurate in every respect. We are working with Translational Drug Development (TD2), Chamow & Associates (Chamow) and Austrianova in completing everything that is required. It is a process that began last year and is well underway.
“TD2 is fully engaged and working diligently in all aspects of preparing for the clinical trial. With respect to developing the CMC information, the process is complicated, labor intensive and highly technical. But with TD2 taking the lead, working in concert with Chamow and Austrianova, I am very confident that our schedule is on track.”